Supelco and MIP Technologies Launch new SPE Product for the Selective Extraction of NSAIDs
News Jul 17, 2009
MIP Technologies AB and Supelco, a division of Sigma-Aldrich announced the launch of a new molecularly imprinted polymer, SPE product, SupelMIP™, for the selective extraction of non-steroidal anti-inflammatory drugs (NSAIDs).
"SupelMIP NSAIDS is an important addition to our portfolio because it targets a critical area of public concern - the increasing appearance of prescription and over-the-counter drugs in environmental water," said Anthony Rees, CEO of MIP Technologies. "This concern is reflected in the programs initiated by many governments to monitor national water resources for the presence and concentrations of the most frequently used drugs having the potential for adverse effects. This product recognizes members of the class of NSAIDs related to ibuprofen and will simplify the analysis of these drugs when present, at even low levels, in natural water samples."
SupelMIP was developed for confirmation and quantitation of NSAID drugs in water samples. The SPE phase has been developed for multi-residue extraction of NSAIDs and has been validated for ibuprofen, diclofenac, naproxen, clofibric acid, celecoxob and piroxicam.
"SupelMIP SPE allows researchers to selectively extract and recover non-steroidal anti-inflammatory drugs," said An Trinh, product manager of Sample Prep at Supelco. "Such compounds are among the most highly consumed pharmaceuticals in the world."
Ibuprofen, diclofenac and naproxen are non-steroidal anti-inflammatory drugs that have analgesic and antipyretic activities. Clofibric acid is an active metabolite of clofibrate, etofibrate and etofyllinclofibrate.
These compounds are used as blood lipid regulators. Because of the pharmacological activity of the NSAIDs and the possibility of entry into the domestic water cycle, the concentrations need to be quantified in natural water samples.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018